Dose Limiting Toxicity (DLT) Up to 1 cycle (21 days) in Phase 1b part [clinicaltrials_resource:634f7015628aca564f0c0f3070348c41]
Subjects with metastatic triple-negative breast cancer previously treated with 0 to 2 chemotherapy regimens in the metastatic setting
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Dose Limiting Toxicity (DLT) Up to 1 cycle (21 days) in Phase 1b part [clinicaltrials_resource:634f7015628aca564f0c0f3070348c41]
Subjects with metastatic triple-negative breast cancer previously treated with 0 to 2 chemotherapy regimens in the metastatic setting
Bio2RDF identifier
634f7015628aca564f0c0f3070348c41
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:634f7015628aca564f0c0f3070348c41
measure [clinicaltrials_vocabulary:measure]
Dose Limiting Toxicity (DLT)
time frame [clinicaltrials_vocabulary:time-frame]
Up to 1 cycle (21 days) in Phase 1b part
description
Subjects with metastatic tripl ...... mens in the metastatic setting
identifier
clinicaltrials_resource:634f7015628aca564f0c0f3070348c41
title
Dose Limiting Toxicity (DLT) Up to 1 cycle (21 days) in Phase 1b part
@en
type
label
Dose Limiting Toxicity (DLT) U ...... f7015628aca564f0c0f3070348c41]
@en